ARA: HUGE POTENTIAL....This is Huge....
"SoftScan system is undergoing multicentre trials in the U.S. and Canada. The Company is aiming to obtain
regulatory approval in Canada, the European Union (EU) and the U.S.
Future applications … and growth potential
told, these potential downstream markets are worth US$20 billion annually."
SoftScan® An optical imaging device developed for the purpose of diagnosing and characterizing
breast cancer. This product is designed to help address critical and unmet needs in
breast tissue analysis and treatment monitoring.
What sets us apart:
• Can provide more accurate characterization of tumours;
SoftScan system is undergoing multicentre trials in the U.S. and Canada. The Company is aiming to obtain
regulatory approval in Canada, the European Union (EU) and the U.S.
Future applications … and growth potential
told, these potential downstream markets are worth US$20 billion annually.
• Unique molecular insights allowing differentiation between
malignant and benign breast lesions;
• Allows imaging of the breast even in women with
radiodense tissue which is impenetrable to conventional
mammography;
• No painful compression of the breast and little
discomfort for the patient;
• Absence of ionizing radiation and non-invasive
procedure;
• Cost-effectiveness.
Surface applications could include the detection and treatment of anomalies in the brain, liver, kidney and prostate;
Equipped with an endoscopic probe, SoftScan has further potential applications in the oral and naso-pharynx
cavities, as well as the oesophagus, stomach, rectum, colon, cervix and uterus.